Chargement en cours...
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Adeno-associated viral (AAV) vectors have emerged as the leading gene delivery platform for gene therapy and vaccination. Three AAV-based gene therapy drugs, Glybera, LUXTURNA, and ZOLGENSMA were approved between 2012–2019 by the European Medicines Agency and the United States Food and Drug Administ...
Enregistré dans:
| Publié dans: | Pharmacol Ther |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6980784/ https://ncbi.nlm.nih.gov/pubmed/31836454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2019.107453 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|